DEA Expands Access to Opioid Treatment Medications

Regulations Revised in Line with the Easy Medication Access and Treatment for Opioid Addiction Act

In a move aimed at mitigating the opioid crisis in the U.S., the Drug Enforcement Administration (DEA) has made revisions to its existing regulations. The adjustments will expand access to vital medications for individuals battling opioid use disorders.

The new regulations stem from the Easy Medication Access and Treatment for Opioid Addiction Act (the Act), directing the DEA to modify its stipulations. Previously, practitioners were restricted to dispensing only a one-day supply of narcotic drugs three times consecutively to relieve acute withdrawal symptoms while a patient awaited referral for further treatment. However, the new rule permits the dispensing of up to a three-day supply at once, aimed at initiating maintenance or detoxification treatment. This regulation comes into effect on August 8, 2023.

The DEA, an authority in implementing and enforcing the Comprehensive Drug Abuse Prevention and Control Act of 1970 and the Controlled Substances Import and Export Act (CSIEA), emphasizes the importance of ensuring a legitimate supply of controlled substances for medical and scientific purposes while preventing their illicit use.

It’s crucial to note the historical context. In October 1974, the DEA issued regulations under the Narcotic Addict Treatment Act, permitting practitioners to administer and dispense certain narcotic medications for detoxification or maintenance, provided they were registered under a narcotic treatment program. The “Three Day Rule,” which has been in force, was aimed at physicians who were not explicitly registered under a narcotic treatment program. The previous rule allowed these physicians to administer – but not prescribe – narcotic drugs for immediate relief from acute withdrawal symptoms.

Fast forward to December 11, 2020, when the Easy Medication Access and Treatment for Opioid Addiction Act was signed into law. This new legislation recognized the importance of timely and adequate medication for opioid-addicted individuals and hence directed the DEA to make the necessary modifications to its existing regulations.

The revisions to the regulations reflect the government’s commitment to addressing the opioid crisis more effectively. By allowing for a three-day medication supply, the DEA believes that individuals will have better access to treatment, leading to better health outcomes and a reduced risk of overdose. This change signifies a crucial step forward in the fight against opioid addiction, with a focus on compassionate care.